The Biostatistics and Bioinformatics Shared Facility serves as a focal point from which cancer investigators draw statistical and bioinformatics expertise for planning, management, and analysis of their studies.

The Comprehensive Genomics Shared Facility supports and maintains state-of-the-art genomic technology platforms including Next-Generation sequencing and high dimensional genotyping platforms and provides access to these resources for cancer investigators. The CGSF is also the dedicated sequencing provider to the Microbiome/Gnotobiotic Shared Facility.

The High Resolution Imaging Shared Facility provides access to instrumentation and technical expertise to support fundamental mechanistic studies and the development and testing of new biomarkers and treatments for cancer.

The Human Imaging Shared Facility provides value-added support for cancer related studies with human imaging components by providing radiology expertise for: standardized protocol review, state-of-the-art image acquisition, standardized tumor metrics quantification and response assessment, development and implementation of new analysis tools and techniques for cancer-related clinical and translational research studies.

The Mass Spectrometry/Proteomics Shared Facility provides state-of-the-art capabilities and training in mass spectrometry, proteomics and bioanalytical technologies to support the research needs of UAB cancer investigators. The MSPSF offers services support the identification, characterization and quantification of proteins, as well as post-translational modifications.

The Microbiome/Gnotobiotics Shared Facility provides cancer investigators with access to cutting-edge microbiome analysis methodologies and gnotobiotic animal models designed to facilitate and strengthen the quality of cancer-related research.

The Pharmacometrics Core offers cancer investigators access to mass spectrometry assay development and state-of-the-art pharmacokinetic and pharmacodynamic data analysis services.

The Preclinical Imaging Shared Facility supports multimodality imaging in preclinical models to accelerate the translation of basic research to human trials. Imaging conducted in the facility currently provides rapid, repeated, accurate, and cost-effective evaluation of new cancer treatments in preclinical models, using the most sophisticated technologies available.

The Recruitment and Retention Shared Facility provides infrastructure to recruit subjects to cancer control and chemoprevention research studies and therapeutic trials, with expertise and emphasis on targeting African Americans, women and older individuals.

The Structural Biology Shared Facility supports cancer investigators with cutting-edge technology to elucidate structure-function relationships of macromolecules. The state-of-the-art research instrumentation capabilities include a Bruker-Biospin Avance III HD 850 MHz NMR spectrometer with a TCI-cryoprobe, a high intensity X-ray system with Pilatus multi-wire and R-axis IV++ detectors, two Fomulatrix crystal imaging systems to support 20o and 4o degree crystallization and imaging, and a powerful optical system that can detect protein crystals less than 1 micron in size.

The Tissue Procurement Shared Facility enhances the productivity and power of research of cancer investigators by ensuring access to high-quality tissue specimens (malignant, normal, benign, diseased) with associated histopathologic and demographic data, histology services, and expertise in informative analysis of tissue samples. The TPSF operates as a state-of-the-art, centralized, investigator-driven tissue procurement service that streamlines functionality, incorporates new technologies into standard operating procedures for sample collection and processing, storage and data tracking. Specimens can be provided to investigators fresh, frozen or fixed.

The Transgenic Animal Shared Facility provides efficient, cost-effective production of transgenic and genetically-engineered animal models for cancer investigators to accelerate genetic, biochemical, and cellular analyses of pathogenic mechanisms of cancer, as well as provide in vivo models for the assessment of human disease alleles and genetic avatars for personalized cancer therapies.